Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncological and Immunological Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CARD11 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CARD11 (WT & Mutant L251P/K287R) Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Sf9/HEK293 Expressed. |
View CARD11 Products |
| Gene Delivery | CARD11 Promise-ORF / Lentivirus Particles Full-length ORF (WT and clinical mutants) for stable NF-κB reporter cell line construction. |
View CARD11 Products |
| Benchmark Ab | Anti-CARD11 Recombinant Antibody High-affinity clone for immunoprecipitation (IP) and western blot (WB) validation. |
View CARD11 Products |
| Validator | CARD11 siRNA Set Target-specific knockdown verification in B-cell lymphoma lines. |
View CARD11 Products |
| Related Target A | MALT1 Downstream protease in the CBM complex; prime target for synergistic small-molecule inhibition. |
View MALT1 Products |
| Related Target B | BCL10 Bridging adaptor protein of the CBM complex essential for NF-κB pathway activation. |
View BCL10 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Disrupting intracellular protein-protein interactions (PPI) | High-purity, sequence-verified CARD11 domain proteins (CARD, LATCH, coiled-coil) for precise in vitro binding assays. |
| Modeling oncogenic gain-of-function (GOF) signaling | Lentiviral vectors carrying key clinical mutants (L251P, K287R) to establish physiologically relevant cellular assays. |
| Lack of Controls | Recombinant positive control antibodies and validation-ready siRNA pools included. |
| False Positives | Isogenic mutant vs. wild-type protein panels to filter out non-specific hydrophobic aggregators. |
Live CARD11 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CARD11 therapeutics is intensifying, with major players shifting focus from traditional systemic immunosuppression to targeted disruption of the CBM (CARD11-BCL10-MALT1) signalosome. As first-generation downstream MALT1 inhibitors reach the clinic, the next wave of R&D is targeting CARD11 directly using small-molecule protein-protein interaction (PPI) inhibitors and PROTAC-mediated degradation to overcome drug resistance in hematological malignancies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitor) | Academic Consortia, Biotech Startups | Diffuse Large B-Cell Lymphoma (DLBCL), BENTA Disease | In vitro binding assays (Need sequence-verified CARD11 domain proteins) |
| PROTAC / Degrader | Targeted Protein Degradation Pioneers | Mantle Cell Lymphoma, Refractory B-cell Malignancies | Ubiquitination & degradation assays (Need high-purity protein and mutant controls) |
| Gene Therapy / RNAi | Preclinical Stage Biopharma | Severe Atopic Dermatitis, Autoimmune disorders | Knockdown validation (Need sequence-specific siRNA sets) |